Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 30 results:
Συντάκτης [ Τίτλος] Τύπος Έτος Φίλτρα: Συντάκτης is Razis, Evangelia [Clear All Filters]
(2013).
Central nervous system tumours among adolescents and young adults (15-39 years) in Southern and Eastern Europe: Registration improvements reveal higher incidence rates compared to the US..
Eur J Cancer. 86, 46-58.
(2017).
(2018).
(2019). Disease evolution and heterogeneity in bilateral breast cancer..
Am J Cancer Res. 6(11), 2611-2630.
(2016). EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab..
J Cancer Res Clin Oncol. 140(5), 737-48.
(2014). Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab..
Cancer Genomics Proteomics. 15(6), 461-471.
(2018).
(2018). The fate of BRCA1-related germline mutations in triple-negative breast tumors..
Am J Cancer Res. 7(1), 98-114.
(2017). Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression..
Clin Breast Cancer. 12(3), 183-93.
(2012).
(2016).
(2013). Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer..
J Exp Clin Cancer Res. 31, 77.
(2012). p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab..
Pathol Oncol Res. 21(2), 273-82.
(2015). Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation..
Anticancer Res. 31(9), 3007-18.
(2011). PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients..
Cancer Chemother Pharmacol. 75(6), 1289-301.
(2015). Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative..
Oncotarget. 11(1), 1-14.
(2020). Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment..
Clin Cancer Res. 15(19), 6258-66.
(2009). Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers..
Cancer Genomics Proteomics. 14(3), 181-195.
(2017). Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab..
Transl Oncol. 12(5), 739-748.
(2019). The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab..
Clin Colorectal Cancer. 12(4), 267-274.e2.
(2013). Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast Cancer..
Anticancer Res. 37(5), 2323-2334.
(2017). Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome..
Clin Breast Cancer. 19(2), 113-125.e4.
(2019). The Role of CXCL13 and CXCL9 in Early Breast Cancer..
Clin Breast Cancer. 20(1), e36-e53.
(2020).
(2010).